Literature DB >> 7837164

Relationship between maternal and neonatal levels of antibodies to 48 kDa SSB(La), 52 kDa SSA(Ro), and 60 kDa SSA(Ro) in pregnancies complicated by congenital heart block.

J P Buyon1, J Waltuck, K Caldwell, B Crawford, S G Slade, J Copel, E K Chan.   

Abstract

OBJECTIVE: Since there is suggestive but, to date, indirect evidence that maternal anti-SSA(Ro) and SSB(La) antibodies are pathogenic in congenital heart block (CHB), we explored the hypothesis that binding to fetal tissues would result in selective depletion of autoantibodies from the neonatal circulation.
METHODS: Maternal and umbilical cord levels of anti-48 kDa SSB(La), anti-52 kDa SSA(Ro) and anti-60 kDa SSA(Ro) antibodies were measured by ELISA and immunoprecipitation at parturition in 15 pregnancies complicated by CHB. A control group consisted of 13 pregnancies in which the mother was known to have antibodies to either SSA(Ro) and/or SSB(La) and the children did not have CHB.
RESULTS: The ratios of maternal to cord serum levels of anti-48 SSB(La), anti-52 SSA(Ro) and anti-60 kDa SSA(Ro) antibodies ranged from 0.71 to 2.38 in both affected and unaffected pregnancies. The mean ratio obtained for each of the 3 autoantibodies was not significantly different between the 2 groups. Moreover these ratios did not significantly differ from the mean ratios obtained for total IgG levels in either group.
CONCLUSION: These data demonstrate that maternal antibodies to all components of the SSA(Ro) SSB(La) system are efficiently transported across the placenta and are not selectively depleted in the circulation of neonates with CHB.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7837164

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  5 in total

Review 1.  Clinical relevance of autoantibodies in systemic rheumatic diseases.

Authors:  M J Fritzler
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

2.  Identification and management of fetuses at risk for, or affected by, congenital heart block associated with autoantibodies to SSA (Ro), SSB (La), or an HsEg5-like autoantigen.

Authors:  Renate Claus; Heiko Hickstein; Thomas Külz; Ute Lenschow; Doris Meiske; Andrea Kotitschke; Hans-Jürgen Thiesen; Peter Lorenz
Journal:  Rheumatol Int       Date:  2006-01-10       Impact factor: 2.631

Review 3.  Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus.

Authors:  Deborah M Friedman; Ann Rupel; Jill P Buyon
Journal:  Curr Rheumatol Rep       Date:  2007-05       Impact factor: 4.592

4.  Clinical characteristics of children with positive anti-SSA/SSB antibodies.

Authors:  Pei-Hsuan Chen; Yao-Hsu Yang; Yu-Tsan Lin; Jyh-Hong Lee; Li-Chieh Wang; Hsin-Hui Yu; Bor-Luen Chiang
Journal:  Rheumatol Int       Date:  2014-08       Impact factor: 3.580

5.  Ro/SSA autoantibodies directly bind cardiomyocytes, disturb calcium homeostasis, and mediate congenital heart block.

Authors:  Stina Salomonsson; Sven-Erik Sonesson; Lars Ottosson; Saad Muhallab; Tomas Olsson; Maria Sunnerhagen; Vijay K Kuchroo; Peter Thorén; Eric Herlenius; Marie Wahren-Herlenius
Journal:  J Exp Med       Date:  2005-01-03       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.